Siemens Fonds Invest GmbH Acquires 2,947 Shares of Abbott Laboratories (NYSE:ABT)

Siemens Fonds Invest GmbH grew its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 5.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 58,605 shares of the healthcare product maker's stock after acquiring an additional 2,947 shares during the quarter. Siemens Fonds Invest GmbH's holdings in Abbott Laboratories were worth $6,611,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. GHE LLC boosted its holdings in shares of Abbott Laboratories by 5.0% in the 4th quarter. GHE LLC now owns 15,190 shares of the healthcare product maker's stock valued at $1,718,000 after buying an additional 718 shares during the last quarter. Cim LLC boosted its holdings in shares of Abbott Laboratories by 0.4% in the 4th quarter. Cim LLC now owns 16,967 shares of the healthcare product maker's stock valued at $1,919,000 after buying an additional 73 shares during the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $83,000. Menard Financial Group LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $115,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Abbott Laboratories in the 4th quarter valued at approximately $158,119,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Price Performance

NYSE:ABT traded up $0.83 during trading hours on Friday, hitting $133.68. The company's stock had a trading volume of 14,235,633 shares, compared to its average volume of 6,164,763. The stock has a fifty day simple moving average of $130.46 and a 200-day simple moving average of $125.17. The company has a market capitalization of $232.58 billion, a P/E ratio of 17.47, a PEG ratio of 2.52 and a beta of 0.74. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.02. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. On average, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ABT has been the subject of several research reports. Barclays raised their price target on Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a report on Thursday, April 17th. Citigroup raised their price target on Abbott Laboratories from $135.00 to $160.00 and gave the company a "buy" rating in a report on Tuesday, March 4th. Bank of America raised their price target on Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a report on Monday, March 10th. Jefferies Financial Group increased their price objective on Abbott Laboratories from $135.00 to $137.00 and gave the stock a "hold" rating in a research report on Thursday, April 17th. Finally, The Goldman Sachs Group increased their price objective on Abbott Laboratories from $138.00 to $154.00 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $142.59.

Insider Activity at Abbott Laboratories

In related news, EVP Lisa D. Earnhardt sold 91,167 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total value of $12,199,967.94. Following the transaction, the executive vice president now directly owns 71,928 shares of the company's stock, valued at $9,625,404.96. The trade was a 55.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Sally E. Blount sold 2,600 shares of Abbott Laboratories stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director now directly owns 34,058 shares in the company, valued at approximately $4,415,960.28. This represents a 7.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 95,278 shares of company stock valued at $12,745,859 over the last ninety days. 0.46% of the stock is owned by corporate insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.